Age Related Macular Degeneration Clinical Trial
Official title:
Pars Plana Vitrecromy in Patients Aged 85 Years and Above
We reviewed the records of 120 consecutive patients (male and female), aged 85 years and above, who underwent pars plana vitrecromy in the Tel Aviv Medical Center during the years 01/01/2006 - 31/12/2013, and were followed by physicians in the ophthalmology department in the center until December 2015.
We reviewed the records of 120 consecutive patients (male and female), aged 85 years and
above, who underwent pars plana vitrecromy in the Tel Aviv Medical Center during the years
01/01/2006 - 31/12/2013, and were followed by physicians in the ophthalmology department in
the center until December 2015. We will be measuring visual acuity, intra-ocular pressure,
demographics (age, gender), indication for surgery, ocular co-morbidities, surgical
parameters (time of surgery, type of anesthesia - general or local, type of suture), and
intraoperative and postoperative complications.
Primary outcome - visual acuity will be measured at base line, after 1 week, 1 month, 3
months, 6 months / last follow up (until December 2015). visual acuity will be determined by
a standardized chart test (Snellen chart). For statistical analysis, all VA values were
converted to logMAR scale. According to Holladay and the University of Freiburg study group
results, blindness was set at 0.00125/2.9 (decimal/logMAR), light perception at 0.0025/2.6,
hand movements at 0.005/2.3 and counting fingers at 0.014/1.85. Data will be analyzed using
SPSS software. A p-value of 0.05 will be considered statistically significant and t-tests
analysis will be used to compare between means.
Secondary outcomes - demographics, Indication for surgery, ocular co morbidities will be
measured at baseline. Surgical parameters and intraoperative complications will be measured
at 1 week. Postoperative complications will be measured during follow up after 1 week, 1
month, 3 months, 6 months / last follow up (until December 2015).
Complications will be measured by examination of intraocular pressure, slit-lamp and fundus
(Ophthalmoscopic Exam).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03963817 -
Snapshot Camera for AMD
|
||
Recruiting |
NCT04929756 -
Eye Movement Rehabilitation in Low Vision Patients
|
||
Completed |
NCT04779398 -
Association of MPOD Values With Blue Light.
|
||
Terminated |
NCT03275753 -
Visual Function Tests in Age-related Macular Degeneration
|
||
Recruiting |
NCT03609307 -
Comparison of Treatment Response to Intravitreal Injection of Combined Propranolol and Bevacizumab Versus Bevacizumab Monotherapy in Patients With Wet Age Related Macular Degeneration :A Clinical Trial
|
Phase 2/Phase 3 | |
Completed |
NCT02909985 -
Visual Activity Evoked by Infrared in Humans After Dark Adaptation
|
N/A | |
Completed |
NCT02556723 -
Intravitreal Injections of Ziv-aflibercept for Macular Diseases
|
N/A | |
Active, not recruiting |
NCT01943396 -
Treatment of AMD With Rheohemapheresis /RHF/
|
Phase 4 | |
Completed |
NCT00963339 -
Age-Related Macular Degeneration (AMD) - Usability Study
|
N/A | |
Completed |
NCT00376701 -
Combination Therapy for Age-Related Macular Degeneration.
|
Phase 2 | |
Terminated |
NCT00347165 -
Intravitreal Bevacizumab for Age-Related Macular Degeneration
|
Phase 2 | |
Completed |
NCT00800995 -
Superoxide Dismutase (SOD) as Antioxidant Treatment OF Age Related Macular Degeneration (ARMD)
|
Phase 3 | |
Completed |
NCT04689789 -
OCTA and Retinal Angiomatous Proliferation
|
||
Completed |
NCT02567604 -
Development of Core Outcomes for Age-related Macular Degeneration (AMD) Interventions- Caregivers' Perspective
|
||
Completed |
NCT02173496 -
Colour Contrast Sensitivity for the Early Detection of Wet Age-related Macular Degereration (CEDAR)
|
||
Recruiting |
NCT01991730 -
Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients
|
N/A | |
Active, not recruiting |
NCT01657669 -
Short-term Clinical Effects of Intravitreal Aflibercept Injection 2.0mg as a Predictor of Long-term Results
|
Phase 4 | |
Completed |
NCT00791570 -
Anti-VEGFR Vaccine Therapy in Treating Patients With Neovascular Maculopathy
|
Phase 1 | |
Completed |
NCT00776763 -
Ocular Growth Factors Profile in Proliferative Retinopathies Before and After Intravitreal Bevacizumab
|
Phase 2 | |
Completed |
NCT00413829 -
Immediate Effects of Lucentis® in Conjunction With Photodynamic Therapy With Visudyne® in Exudative AMD(IECOMB)
|
Phase 2 |